Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,19262560,t(1/2),"In study 1, serum CTLA4Ig concentrations climbed rapidly to the peak and declined slowly with a t(1/2) of 15.1+/-2.6 d, 14.2+/-2.3 d, and 11.8+/-1.2 d after a single infusion of 1, 10, and 20 mg/kg, respectively.",Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19262560/),d,15.1,83694,DB01281,Abatacept
,19262560,t(1/2),"In study 1, serum CTLA4Ig concentrations climbed rapidly to the peak and declined slowly with a t(1/2) of 15.1+/-2.6 d, 14.2+/-2.3 d, and 11.8+/-1.2 d after a single infusion of 1, 10, and 20 mg/kg, respectively.",Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19262560/),d,14.2,83695,DB01281,Abatacept
,19262560,t(1/2),"In study 1, serum CTLA4Ig concentrations climbed rapidly to the peak and declined slowly with a t(1/2) of 15.1+/-2.6 d, 14.2+/-2.3 d, and 11.8+/-1.2 d after a single infusion of 1, 10, and 20 mg/kg, respectively.",Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19262560/),d,11.8,83696,DB01281,Abatacept
,19262560,peak,"In study 2, the steady-state condition for CTLA4Ig following multiple doses of 10 mg/kg appeared to be attained at the fourth dose (d 56), with peak and trough concentrations of 239.8+/-45.3 mg/L and 20.5+/-7.9 mg/L, respectively.",Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19262560/),[mg] / [l],239.8,83697,DB01281,Abatacept
,19262560,trough concentrations,"In study 2, the steady-state condition for CTLA4Ig following multiple doses of 10 mg/kg appeared to be attained at the fourth dose (d 56), with peak and trough concentrations of 239.8+/-45.3 mg/L and 20.5+/-7.9 mg/L, respectively.",Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19262560/),[mg] / [l],20.5,83698,DB01281,Abatacept
,19262560,terminal half-life,"After multiple infusions, serum concentrations dropped slowly and the terminal half-life was 12.6+/-4.7 d.",Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19262560/),d,12.6,83699,DB01281,Abatacept
,24217983,maximum serum concentration,"Following multiple doses of 5 or 10 mg/kg, the geometric mean (percentage coefficient of variation) maximum serum concentration and area under the serum concentration-time curve over one dosing interval of belatacept were 136 (20%) and 238 (27%) μg/mL, and 13,587 (27%) and 21,241 (35%) μg·h/mL, respectively.","Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217983/),[μg] / [ml],136,105113,DB01281,Abatacept
,24217983,maximum serum concentration,"Following multiple doses of 5 or 10 mg/kg, the geometric mean (percentage coefficient of variation) maximum serum concentration and area under the serum concentration-time curve over one dosing interval of belatacept were 136 (20%) and 238 (27%) μg/mL, and 13,587 (27%) and 21,241 (35%) μg·h/mL, respectively.","Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217983/),[μg] / [ml],238,105114,DB01281,Abatacept
,24217983,maximum serum concentration,"Following multiple doses of 5 or 10 mg/kg, the geometric mean (percentage coefficient of variation) maximum serum concentration and area under the serum concentration-time curve over one dosing interval of belatacept were 136 (20%) and 238 (27%) μg/mL, and 13,587 (27%) and 21,241 (35%) μg·h/mL, respectively.","Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217983/),,"13,587",105115,DB01281,Abatacept
,24217983,area under the serum concentration-time curve,"Following multiple doses of 5 or 10 mg/kg, the geometric mean (percentage coefficient of variation) maximum serum concentration and area under the serum concentration-time curve over one dosing interval of belatacept were 136 (20%) and 238 (27%) μg/mL, and 13,587 (27%) and 21,241 (35%) μg·h/mL, respectively.","Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217983/),,"13,587",105116,DB01281,Abatacept
,24217983,area under the serum concentration-time curve,"Following multiple doses of 5 or 10 mg/kg, the geometric mean (percentage coefficient of variation) maximum serum concentration and area under the serum concentration-time curve over one dosing interval of belatacept were 136 (20%) and 238 (27%) μg/mL, and 13,587 (27%) and 21,241 (35%) μg·h/mL, respectively.","Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217983/),,"21,241",105117,DB01281,Abatacept
,24217983,elimination half-life,The median belatacept elimination half-life was 8-9 days.,"Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217983/),d,8-9,105118,DB01281,Abatacept
,24217983,trough serum concentrations,"The pre-dose CD86 receptor occupancy by belatacept decreased from 94 to 65% between day 5 and 1 year post-transplant, with corresponding pre-dose trough serum concentrations of belatacept decreasing from ~35 to 4 μg/mL during this period.","Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217983/),[μg] / [ml],35,105119,DB01281,Abatacept
,24217983,trough serum concentrations,"The pre-dose CD86 receptor occupancy by belatacept decreased from 94 to 65% between day 5 and 1 year post-transplant, with corresponding pre-dose trough serum concentrations of belatacept decreasing from ~35 to 4 μg/mL during this period.","Pharmacokinetics, pharmacodynamics, and immunogenicity of belatacept in adult kidney transplant recipients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24217983/),[μg] / [ml],4,105120,DB01281,Abatacept
≥,33284480,Cminss,Cminss was the best exposure predictor for the JIA-ACR response: log odds for response increased in proportion to log-transformed Cminss ; JIA-ACR30 approached a plateau when Cminss ≥ 10 μg/mL.,Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33284480/),[μg] / [ml],10,129239,DB01281,Abatacept
,9244149,absolute SC bioavailability,"The absolute SC bioavailability of CTLA4Ig decreased as the dose increased from 10 (62.5%), 80 (55.7%), and 200 mg/kg (41.1%).","Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244149/),%,62.5,204630,DB01281,Abatacept
,9244149,absolute SC bioavailability,"The absolute SC bioavailability of CTLA4Ig decreased as the dose increased from 10 (62.5%), 80 (55.7%), and 200 mg/kg (41.1%).","Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244149/),%,55.7,204631,DB01281,Abatacept
,9244149,absolute SC bioavailability,"The absolute SC bioavailability of CTLA4Ig decreased as the dose increased from 10 (62.5%), 80 (55.7%), and 200 mg/kg (41.1%).","Assessment of dose proportionality, absolute bioavailability, and immunogenicity response of CTLA4Ig (BMS-188667), a novel immunosuppressive agent, following subcutaneous and intravenous administration to rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9244149/),%,41.1,204632,DB01281,Abatacept
,24708204,Serious adverse event frequencies,Serious adverse event frequencies (5.1% vs. 3.4%) were similar with both formulations.,"Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24708204/),%,5.1,210418,DB01281,Abatacept
,24708204,Serious adverse event frequencies,Serious adverse event frequencies (5.1% vs. 3.4%) were similar with both formulations.,"Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24708204/),%,3.4,210419,DB01281,Abatacept
,30582294,half-life (T1/2 ),Mean half-life (T1/2 ) occurred 7.2 days postinfusion.,Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30582294/),d,7.2,213884,DB01281,Abatacept
,30582294,total body clearance,"Belatacept total body clearance was 0.48 mL/h/kg, and volume of distribution at steady-state (Vss ) was low at 0.09 L/kg.",Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30582294/),[ml] / [h·kg],0.48,213885,DB01281,Abatacept
,30582294,volume of distribution at steady-state (Vss ),"Belatacept total body clearance was 0.48 mL/h/kg, and volume of distribution at steady-state (Vss ) was low at 0.09 L/kg.",Phase I study of single-dose pharmacokinetics and pharmacodynamics of belatacept in adolescent kidney transplant recipients. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30582294/),[l] / [kg],0.09,213886,DB01281,Abatacept
,9127268,100% serum equivalent curve,This EIA has a range of reliable response in 10% mouse serum of 0.14-4.58 ng ml-1 resulting in a 100% serum equivalent curve of 1.4-45.8 ng ml-1.,A sensitive enzyme immunoassay for the quantitation of human CTLA4Ig fusion protein in mouse serum: pharmacokinetic application to optimizing cell line selection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9127268/),[ng] / [ml],1.4-45.8,226341,DB01281,Abatacept
,9127268,LLQ,The LLQ was established at 1.4 ng ml-1.,A sensitive enzyme immunoassay for the quantitation of human CTLA4Ig fusion protein in mouse serum: pharmacokinetic application to optimizing cell line selection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9127268/),[ng] / [ml],1.4,226342,DB01281,Abatacept
≥,28822046,Cmin,Median Cmin abatacept concentration was ≥ 10 μg/mL (efficacy threshold) at 3 and 6 months in > 90% of patients across BMI groups with both administration routes.,Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28822046/),[μg] / [ml],10,256751,DB01281,Abatacept
≥,30229926,Cminss,Efficacy responses increased with increasing Cminss and a near-maximal response was associated with Cminss ≥10 μg/mL.,Population Pharmacokinetics and Exposure-Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229926/),[μg] / [ml],10,262372,DB01281,Abatacept
≥,30229926,Cminss,"The model-based analyses confirmed that the weight-tiered ∼10 mg/kg IV and fixed 125 mg SC abatacept dosing regimens are comparable and achieved plateau responses, by delivering Cminss ≥10 μg/mL in RA patients across all body weights.",Population Pharmacokinetics and Exposure-Response Relationship of Intravenous and Subcutaneous Abatacept in Patients With Rheumatoid Arthritis. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229926/),[μg] / [ml],10,262373,DB01281,Abatacept
